The European Securities and Markets Authority (ESMA) has published today an update of its list of central clearinghouses, also known as central counterparties (CCPs) which are authorised under the European Markets Infrastructure Regulation (EMIR).
Today’s update concerns CME Clearing Europe Ltd. which has extended its activities and services, a fact which under EMIR requires a new authorization by the competent authority. CME Europe has been committed to establishing an authorised CCP facility for some time, with LeapRate having broken the news in August 2014 that the company had been provided with initial authorization under EMIR covering all OTC derivatives and futures products currently cleared by CME Clearing Europe.
As a result of that approval, CME Clearing Europe Ltd. was first authorised on 4 August 2014. It has now been re-authorized for extended activities and services.
For the official announcement from ESMA, click here.